177 related articles for article (PubMed ID: 33806464)
21. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.
Ziai D; Wagner T; El Badaoui A; Hitzel A; Woillard JB; Melloni B; Monteil J
Cancer Imaging; 2013 Mar; 13(1):73-80. PubMed ID: 23466871
[TBL] [Abstract][Full Text] [Related]
22. The role of interim
Sachpekidis C; Anwar H; Winkler J; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079
[TBL] [Abstract][Full Text] [Related]
23. Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods.
Ayati N; Lee ST; Zakavi SR; Cheng M; Lau WFE; Parakh S; Pathmaraj K; Scott AM
J Nucl Med; 2021 Jul; 62(7):926-933. PubMed ID: 33246978
[TBL] [Abstract][Full Text] [Related]
24. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
[TBL] [Abstract][Full Text] [Related]
25. Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria.
Velez EM; Desai B; Ji L; Quinn DI; Colletti PM; Jadvar H
Theranostics; 2020; 10(7):3254-3262. PubMed ID: 32194866
[TBL] [Abstract][Full Text] [Related]
26. Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?
Rendl G; Schweighofer-Zwink G; Sorko S; Gallowitsch HJ; Hitzl W; Reisinger D; Pirich C
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454777
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.
Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635
[TBL] [Abstract][Full Text] [Related]
28. Assessment of tumor response to definitive chemoradiotherapy and prognosis prediction in patients with esophageal cancer judged by PET response criteria in solid tumors: multicenter study in Japan.
Kitajima K; Kaida H; Nakatani K; Ishibashi M; Morita T; Nakajo M; Tamaki Y; Minamimoto R
Nucl Med Commun; 2020 May; 41(5):443-451. PubMed ID: 32187159
[TBL] [Abstract][Full Text] [Related]
29. Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?
Gupta M; Choudhury PS; Jain P; Sharma M; Koyyala VPB; Goyal S; Agarwal C; Jajodia A; Pasricha S; Sharma A; Batra U
World J Nucl Med; 2022 Mar; 21(1):34-43. PubMed ID: 35502277
[No Abstract] [Full Text] [Related]
30. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for response evaluation in recurrent carcinoma cervix: does metabolic response predict survival?
Dhull VS; Sharma P; Sharma DN; Maharjan S; Suman Kc S; Patel C; Bal C; Kumar R
Int J Gynecol Cancer; 2014 Feb; 24(2):312-20. PubMed ID: 24407578
[TBL] [Abstract][Full Text] [Related]
31.
Niccoli Asabella A; Di Palo A; Altini C; Fanelli M; Ferrari C; Lavelli V; Ranieri G; Gadaleta CD; Rubini G
Hell J Nucl Med; 2018; 21(3):191-197. PubMed ID: 30411729
[TBL] [Abstract][Full Text] [Related]
32. Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST.
Katsuura T; Kitajima K; Fujiwara M; Terada T; Uwa N; Noguchi K; Doi H; Tamaki Y; Yoshida R; Tsuchitani T; Fujita M; Yamakado K
Ann Nucl Med; 2018 Aug; 32(7):453-462. PubMed ID: 29858797
[TBL] [Abstract][Full Text] [Related]
33. Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0.
Kitajima K; Miyoshi Y; Yamano T; Odawara S; Higuchi T; Yamakado K
Nagoya J Med Sci; 2018 May; 80(2):183-197. PubMed ID: 29915436
[TBL] [Abstract][Full Text] [Related]
34. Comparison of prognostic value of different metabolic response criteria determined by PET/CT in patients with metastatic breast cancer under CDK 4/6 inhibitor treatment.
Önner H; Eren OÖ; Körez MK; Yilmaz F; Kara Gedik G
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(5):319-324. PubMed ID: 37030597
[TBL] [Abstract][Full Text] [Related]
35. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
Lopci E; Zucali PA; Ceresoli GL; Perrino M; Giordano L; Gianoncelli L; Lorenzi E; Gemelli M; Santoro A; Chiti A
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):667-75. PubMed ID: 25403555
[TBL] [Abstract][Full Text] [Related]
36. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer.
Kaira K; Yamaguchi O; Naruse I; Umeda Y; Honda T; Watanabe S; Ichikawa K; Yanagisawa S; Kasahara N; Higuchi T; Hashimoto K; Miura Y; Shiono A; Mouri A; Imai H; Iizuka K; Ishizuka T; Minato K; Suda S; Kagamu H; Mori K; Seki N; Kuji I
Cancer Imaging; 2023 Mar; 23(1):23. PubMed ID: 36859341
[TBL] [Abstract][Full Text] [Related]
38. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.
Riedl CC; Pinker K; Ulaner GA; Ong LT; Baltzer P; Jochelson MS; McArthur HL; Gönen M; Dickler M; Weber WA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1428-1437. PubMed ID: 28462446
[TBL] [Abstract][Full Text] [Related]
39. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point
Cho SY; Lipson EJ; Im HJ; Rowe SP; Gonzalez EM; Blackford A; Chirindel A; Pardoll DM; Topalian SL; Wahl RL
J Nucl Med; 2017 Sep; 58(9):1421-1428. PubMed ID: 28360208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]